Web developed by Josh Bolinger website design

The Global Leader in Preclinical Ophthalmic Research


Proprietary MiDROPS™ technology is also available to formulate small lipohilic molecules for topical instillation (eyedrop).  This patented technology platform can deliver test agents to both the anterior and posterior segments of the eye.



EyeCRO provides numerous in-vivo research models to enable directed and meaningful preclinical drug discovery and development programs. EyeCRO also has extensive experience in various routes of administration and can customize studies depending on your needs. One of the main advantages in working with EyeCRO is our ability to be flexible.

EyeCRO and MPI Research Partner to Develop New Preclinical Models of Ophthalmic Disease

Oklahoma City, OK; Ann Arbor, MI; and Mattawan, MI (PRWEB) May 01, 2017 EyeCRO and MPI Research, … Read More

Inhibition of Stat3 by a Small Molecule Inhibitor Slows Vision Loss in a Rat Model of Diabetic Retinopathy

"Diabetic retinopathy is a leading cause of vision loss. Previous studies have shown signaling … Read More

Serum retinol-binding protein-induced endothelial inflammation is mediated through the activation of toll-like receptor 4

"Retinol-binding protein 4 (RBP4) is a novel adipokine (adipose-derived cytokine) that is clinically … Read More

More News

Wednesday, March 14th, 2018 at 4:14am
“Remember to look up at the stars and not down at your feet. Try to make sense of what you see and about what makes the universe exist. Be curious. And however difficult life may seem, there is always something you can do, and succeed at. It matters that you don’t just give up.” https://t.co/Dfb9cVBdgV EyeCRO photo
Preclinical Ophthalmic Contract Research